Knockdown of SPOP or expression of prostate cancer-associated SPOP mutants sensitized prostate cancer cells to PARP inhibitor, olaparib, as was seen in BRCA1-depleted cells [36,61]. This evidence concerns the gene PARP1 and prostate cancer.